Grand Rounds February 24, 2023: S2302 Pragmatica-Lung: New Directions for Decreasing Burden and Increasing Inclusion in NCTN Clinical Trials (Konstantin Dragnev, MD; Karen Reckamp, MD, MS)
Rethinking Clinical Trials
MARCH 1, 2023
We got both Merck and Lily to work together in the Phase II trial, then the data from that trial that showed survival benefit led to the Phase III study. There is a strong mechanistic rationale. They are both approved and used widely in lung cancer, and combining two existing agents is logistically and clinically simpler.
130 
Let's personalize your content